SAN ANTONIO--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today presented data from an ongoing ...
News
- Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in ...
- Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San ...
... clinical data presentations at the San Antonio Breast Cancer Symposium, ... Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company ...
- KU professor's research proves some science textbooks wrong
Haufler's research is reported in the November issue of the journal Bioscience, in an article he co-authored with a group he said one reviewer ...
- Study: IBM Watson agrees with cancer docs on treatment options 90% of the time
At the San Antonio Breast Cancer Symposium, Dr. S. P. Somashekhar, chairman of the Manipal Comprehensive Cancer Center in Bengaluru, India, ...
- Puma Biotechnology, Inc. (NYSE:PBYI) announced interim results from a Phase II clinical trial
Puma Biotechnology, Inc. (NYSE:PBYI) traded 1.42 Million shares and was closed at $36.45 per share. The current share price indicates that stock is ...